- Home
- HMR vs SKYE Comparison
HMR vs SKYE Comparison
Compare HMR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HMR | SKYE |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | Greece | United States |
| Employees | 57 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 44.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HMR | SKYE |
|---|---|---|
| Price | $1.08 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | ★ $14.75 |
| AVG Volume (30 Days) | 35.5K | ★ 260.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.26 | N/A |
| Revenue Next Year | $45.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.68 |
| 52 Week High | $4.80 | $5.75 |
Technical Indicators
Market Signals| Indicator | HMR | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 42.72 |
| Support Level | $0.88 | $0.68 |
| Resistance Level | $1.34 | $0.83 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.73 | 57.58 |
Price Performance
Historical ComparisonAbout HMR Heidmar Maritime Holdings Corp.
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.